Improved production of phenomycin by a genetically engineered Escherichia coli.
We established an improved production of an antitumor polypeptide anti biotic, phenomycin (PHM), by using a genetically engineered Escherichia coli. Phenomycin consists of 89 natural amino acids without intramolecular disulfide bridge. PHM gene was synthesized as a fusion gene in which PHM at the C-terminus and the residues 1 approximately 20 of Hirudin variant 1 (HV1) at the N-terminus connected by a factor Xa recognition sequence (Ile-Glu-Gly-Arg). E coli JM 109 transformed with a plasmid containing the synthesized gene expressed a fusion protein and the trypsinization of the fusion protein purified by ultrafiltration and ion-exchange chromatography gave efficiently recombinant PHM at a final yield of 50 mg/liter of culture. This PHM yield was six times higher than that obtained by a natural PHM producing strain of Streptoverticillium baldacci. Recombinant PHM was not distinguishable from natural PHM in all aspects observed.
Nagano
Y
Y
Pharmaceuticals & Biotechnology Laboratory, Japan Energy Corporation, Saitama, Japan.
Takeuchi
N
N
Muramatsu
R
R
Ohba
Y
Y
Abe
S I
SI
Hayashi
H
H
Inouye
Y
Y
D000900:Anti-Bacterial Agents / Q000096:biosynthesis*; D000903:Antibiotics, Antineoplastic / Q000096:biosynthesis*; D004926:Escherichia coli / Q000235:genetics; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D011994:Recombinant Proteins / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D011994:Recombinant Proteins; C072155:phenomycin